VK2735: Mechanism, Trials, and What the Data Actually Shows
VK2735 is a Phase 3 program from Viking Therapeutics built around GLP-1/GIP. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Viking Therapeutics
Mechanism
GLP-1/GIP
Stage
Phase 3
Tracked in
Dual agonists
Approval and timeline
Need the straight approval read on VK2735?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View VK2735 statusCompound facts for search and AI answers
What this VK2735 tracking page answers
Compound
VK2735 from Viking Therapeutics
VK2735 is tracked in the dual agonists group.
Mechanism
GLP-1/GIP
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 3
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Evidence read
14.7% in VANQUISH
VK2735 should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as 14.7%, tied to VANQUISH. This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness. The next listed milestone is 2026. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Latest FormBlends pipeline read
Trial program
VANQUISH
Weight loss signal
14.7%
Administration
Oral and injectable
Next milestone
2026
Rapid weight loss in a short Phase 2 trial duration. Developing both injectable and oral formulations simultaneously from a smaller, more agile biotech company. Phase 2 showed 14.7% body weight reduction in just 13 weeks with the injectable formulation. An oral version is also in development.
Clinical evidence snapshot
What the evidence can and cannot say about VK2735
VK2735 should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as 14.7%, tied to VANQUISH. This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness. The next listed milestone is 2026. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is VK2735 available now or watchlist only?
VK2735 should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- VK2735
- Developer
- Viking Therapeutics
- Stage
- Phase 3
- Mechanism
- Dual agonists
Step 1
Read the stage first
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is VK2735?
VK2735 is a phase 3 obesity or metabolic program from Viking Therapeutics built around GLP-1/GIP.
Is VK2735 approved?
No. VK2735 is not approved yet. It is still a Phase 3 asset and should be viewed as a high-importance near-term pipeline story, not a current product.
When could it matter?
2027 is the optimistic window if the late-stage path stays clean.
What VK2735 is
VK2735 is part of the dual agonists cluster in the FormBlends obesity-pipeline map. We track it because Viking Therapeutics is using GLP-1/GIP as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.
What FormBlends is watching next
For VK2735, the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More dual agonists on FormBlends
Frequently asked questions
What is VK2735?
VK2735 is a Phase 3 obesity or metabolic compound from Viking Therapeutics. FormBlends tracks it in the dual agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does VK2735 work?
VK2735 is being tracked as a GLP-1/GIP program. That mechanism is the main reason it sits inside the dual agonists bucket of the 2026 obesity pipeline.
Is VK2735 available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking VK2735?
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.